Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
Popular Articles
Stretch Mark

Bevacizumab (Avastin(R)) Added To Common Chemotherapies Significantly Increases Tumour Shrinkage In HER2-negative Breast Cancer
Data presented at the American Society of Clinical Oncology (ASCO) 2009 meeting, in Orlando, Florida, show that bevacizumab (Avastin®) plus commonly used chemotherapies increases the chance of the patient living without the disease worsening by up to 36% compared to chemotherapies alone, in women receiving first-line therapy for advanced HER2-negative breast cancer. The Phase III RIBBON-1 study combined bevacizumab with chemotherapies, including capecitabine (Xeloda®), taxanes and anthracyclines and measured progression-free survival (PFS).1 No new safety signals for bevacizumab were observed in the study.
generic viagra online
AVI BioPharma, Inc. Presents At American Society Of Virology Annual Meeting
AVI BioPharma, Inc. (NASDAQ: AVII), a developer of RNA-based drugs, today announced that Dr. Fred Schnell of AVI presented at the American Society of Virology Annual Meeting which took place July 11-15 in Vancouver, B.C. The title of the presentation was "Pan-Arenavirus Antisense Therapeutic Based On PMOplus™ Chemistry." In addition to Dr. Schnell, Drs. Bestwick, Iversen and Mourich, all of AVI, coauthored the presentation.
News of the day
Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results For Radezolid In Community-Acquired Pneumonia
Rib-X Pharmaceuticals, Inc. ("Rib-X" or the "Company"), a development-stage company focused on the discovery, development and commercialization of novel antibiotics for the treatment of antibiotic-resistant infections, today announced positive results from a Phase 2 clinical trial of radezolid in the treatment of community-acquired pneumonia (CAP).
Endocrinology

Comment On Dimebolin (dimebon) Increasing Brain Beta Amyloid In Mouse Models

Dimebolin, originally administered as an antihistamine, has previously been found to help slow the decline of cognitive ability in participants. This study analysed tau and how dimebolin affects build up of the toxic beta amyloid protein, which is widely believed to be linked to the development of dementia. This research showed that while dimebolin had a beneficial effect it actually caused an increase of the beta amyloid in mouse models. "This head scratching research has thrown up surprising results and suggests that while dimebolin provides cognitive benefits it may actually increase levels of toxic beta amyloid in the brain. One possible explanation may be that dimebolin is accelerating the process of beta amyloid development, which may reduce its toxicity. The questions surrounding whether beta amyloid causes nerve death in Alzheimer"s or is a bi-product of the process must be addressed by further research. "One in three people over 65 will die with dementia. Further, more robust research is needed to clarify whether dimebolin is an effective treatment for Alzheimer"s in the long term and if these puzzling increases in beta amyloid are also seen in human brains. With the right investment, dementia can be defeated. Alzheimer"s Society funds research to improve the lives of people today and to find a cure for tomorrow." Professor Clive Ballard Director of Research Alzheimer"s Society Reference: Samuel Gandy, Dimebon regulates amyloid beta metabolism in cultured cells, isolated nerve terminals and interstitial fluid of living rodent brain. Alzheimer"s Society


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009